| 摘要 |
<p>We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt- Jakob disease, stroke, epilepsy, and brain trauma.</p> |
| 申请人 |
JOSLIN DIABETES CENTER;ACTIVESITE PHARMACEUTICALS, INC.;AIELLO, LLOYD, P.;CHILCOTE, TAMIE, JO;SINHA, SUKANTO;FEENER, EDWARD, P. |
发明人 |
FEENER, EDWARD, P. |
